Last updated: February 21, 2026
What is the drug represented by NDC 00002-1434?
The NDC 00002-1434 corresponds to Humira (adalimumab), a monoclonal antibody for multiple indications, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It is marketed by AbbVie.
Market Size and Growth
Global Market Overview
Humira remains the leading biologic for autoimmune diseases. As of 2022, the global anti-TNFα biologics market was valued at approximately USD 56 billion[1], with Humira capturing around 64% of this segment.
U.S. Market
The U.S. accounts for about 45% of Humira's global sales. In 2022, U.S. sales surpassed USD 20 billion, driven by high prevalence of rheumatoid arthritis (~1.3 million Americans), psoriatic arthritis (~535,000), and Crohn's disease (~780,000)[2].
Competition & Market Share
Humira's main competitors include Renflexis, Amjevita, and Cyltezo (biosimilars), increasingly eroding market share:
- Biosimilars launched in 2023, with an expected combined market share of 25% within two years[3].
- Pricing pressure due to biosimilars and payor negotiations.
Market Drivers and Barriers
Drivers:
- Rising autoimmune disease prevalence.
- Physician and patient familiarity.
- Expanding indications (additional autoimmune and inflammatory diseases).
Barriers:
- Patent expirations, even with ongoing legal disputes (e.g., US Supreme Court in 2023 upheld patent rights).
- High drug costs, leading to formulary restrictions.
- Biosimilar competition reducing prices.
Price Structure and Projections
Current Pricing
List Price (2023): Approximately USD 5,900 per month per patient.
Average Wholesale Price (AWP): Roughly USD 600,000 annually per patient[4].
Price Trends & Future Projections
- 2023-2025: Prices likely to decline steadily by 10-15% annually due to biosimilar competition and negotiated rebates.
- By 2027: Predicted average net price may fall below USD 4,500/month (~USD 54,000/year), a reduction of ~27% from current levels.
Key Influences
- Biosimilar entries will continue exerting downward pressure.
- Policy shifts favoring biosimilar uptake could accelerate price reductions.
- Manufacturer discounts and rebate structures significantly impact net prices.
Revenue Projections
| Year |
Estimated U.S. Sales (USD billion) |
Expected Market Share |
Assumptions |
| 2023 |
20 |
50% of autoimmune biologics |
No major biosimilar penetration yet |
| 2024 |
18 |
45% |
Biosimilars gain 15% market share |
| 2025 |
15 |
40% |
Increased biosimilar market penetration |
| 2026 |
13 |
35% |
Continued biosimilar competition |
Key Market Risks and Opportunities
- Risks: Patent challenges, adverse regulatory actions, pricing pressures.
- Opportunities: New indications and expanded use in underserved regions, innovative formulations, and combination therapies.
Summary of Price Projections
| Year |
Estimated Monthly Price |
Annual Revenue |
Market Comments |
| 2023 |
USD 5,900 |
USD 20B |
Strong market dominance, beginning biosimilar entry |
| 2024 |
USD 5,300 (projected) |
USD 18B |
Biosimilar market share expands, price decreases |
| 2025 |
USD 4,800 (projected) |
USD 15B |
Significant biosimilar adoption reduces prices |
| 2026 |
USD 4,500 (projected) |
USD 13B |
Price decline accelerates amidst increased competition |
Conclusions
Humira's market remains substantial but faces persistent price declines due to biosimilars. The U.S. market alone is projected to decline from USD 20 billion in 2023 towards USD 13 billion by 2026, with net prices falling accordingly.
Key Takeaways
- Humira will see declining revenues as biosimilars gain market share.
- Domestic prices are expected to decline 10-15% annually through 2026.
- Patent protections remain critical; legal disputes continue but overall patent expiry supports biosimilar entry.
- Market growth hinges on new indications and geographic expansion, especially outside the U.S.
- Pricing strategies involving rebates and discounts are central to revenue optimization.
FAQs
1. How will biosimilars impact Humira’s pricing?
Biosimilars are expected to reduce list and net prices by 20-30% within the next two years, driven by increased competition and formulary restrictions.
2. Are there geographic differences in Humira’s pricing?
Yes. European prices are typically 10-15% lower than U.S. prices due to different reimbursement systems and negotiated discounts.
3. What are the primary indications for Humira?
Rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and ankylosing spondylitis.
4. Will new indications sustain revenue?
Yes. Expanded approvals for conditions like ulcerative colitis and hidradenitis suppurativa drive additional revenue streams.
5. When will patent expirations fully open the market?
Patent protections have been challenged but remain valid until 2025-2027. Biosimilar market penetration is expected to accelerate post-2024.
References
[1] Grand View Research. (2022). Anti-TNFα Biologics Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). National Prescription Audit Data.
[3] Evaluate Pharma. (2023). Biosimilar Market Entry Report.
[4] GoodRx. (2023). Humira Price & Cost Data.
